Enrolling by invitationNo phase
RACE 2: a Long Term Follow-up of Patients Participating in the RACE Trial
Key facts
- Who runs it
- European Society for Blood and Marrow Transplantation
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Enrolling by invitation
- People taking part
- 197 people, planned
- Started
- Oct 2021
- Expected to end
- Dec 2034
- Type of study
- Observational
- Treatments tested
- ATGAM plus CsA with or without Eltrombopag
- Record updated
- 27 September 2021
Who can take part
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Subject participated in the RACE trial (NCT02099747, EudraCT number: 2014-000363-40) during which patient received ATGAM, Cyclosporine A with or without Eltrombopag
- Subject has provided informed consent to participate in long-term data collection
Who cannot take part
- None
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
After exiting the RACE trial (NCT02099747) patients will be invited to participate in this long term follow-up study
The group in the trial
- RACE 1 patients
After exiting the RACE trial (NCT02099747) patient will be invited to participate in this study
Treatment: ATGAM plus CsA with or without Eltrombopag
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Long-term Follow-up of Patients Participating in RACE: the Prospective Randomized Multicenter Study Comparing Horse Antithymocyte Globuline (hATG) + Cyclosporine A (CsA) With or Without Eltrombopag as Front-line Therapy for Severe Aplastic Anemia Patients
- Record updated
- 27 September 2021